Abiomed Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abiomed in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Abiomed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABMD, but not buy additional shares or sell existing shares.
View analyst ratings for Abiomed or view top-rated stocks.

4 Wall Street analysts have issued 12 month target prices for Abiomed's shares. Their ABMD stock forecasts range from $275.00 to $410.00. On average, they anticipate Abiomed's stock price to reach $335.00 in the next year. This suggests a possible upside of 31.2% from the stock's current price.
View analysts' price targets for Abiomed or view top-rated stocks among Wall Street analysts.

Abiomed's stock was trading at $359.17 at the start of the year. Since then, ABMD stock has decreased by 28.9% and is now trading at $255.40.
View the best growth stocks for 2022 here.

Abiomed is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Abiomed.

Abiomed, Inc. (NASDAQ:ABMD) posted its earnings results on Thursday, April, 28th. The medical equipment provider reported $1.16 EPS for the quarter, beating the consensus estimate of $1.08 by $0.08. The medical equipment provider earned $269.50 million during the quarter, compared to the consensus estimate of $267.67 million. Abiomed had a net margin of 13.23% and a trailing twelve-month return on equity of 14.47%. Abiomed's revenue was up 11.7% compared to the same quarter last year. During the same period last year, the firm posted $1.24 EPS.
View Abiomed's earnings history.

Abiomed updated its FY 2023 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.14 billion-$1.18 billion, compared to the consensus revenue estimate of $1.17 billion.

96 employees have rated Abiomed CEO Michael R. Minogue on Glassdoor.com. Michael R. Minogue has an approval rating of 72% among Abiomed's employees.

Some companies that are related to Abiomed include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), ResMed (RMD), DexCom (DXCM), IDEXX Laboratories (IDXX), STERIS (STE), Hologic (HOLX), Insulet (PODD) and Teleflex (TFX).
View all of ABMD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Abiomed investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Intuitive Surgical (ISRG), Square (SQ), Netflix (NFLX), Adobe (ADBE) and Salesforce (CRM).

Abiomed trades on the NASDAQ under the ticker symbol "ABMD."

Abiomed's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.79%), BlackRock Inc. (10.03%), Baillie Gifford & Co. (8.15%), State Street Corp (4.43%), Wellington Management Group LLP (4.20%) and Primecap Management Co. CA (3.54%). Company insiders that own Abiomed stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Joseph Riccelli, Magdalena Yesil, Martin P Sutter, Michael R Minogue, Michael R Minogue, Paul Thomas and Todd A Trapp.
View institutional ownership trends for Abiomed.

ABMD stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Baillie Gifford & Co., Gilder Gagnon Howe & Co. LLC, William Blair Investment Management LLC, JPMorgan Chase & Co., Tobam, Primecap Management Co. CA, and Canada Pension Plan Investment Board. Company insiders that have sold Abiomed company stock in the last two years include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Joseph Riccelli, Magdalena Yesil, Martin P Sutter, Michael R Minogue, Paul Thomas, and Todd A Trapp.
View insider buying and selling activity for Abiomed or view top insider-selling stocks.

ABMD stock was purchased by a variety of institutional investors in the last quarter, including Winslow Capital Management LLC, Peregrine Capital Management LLC, New York State Common Retirement Fund, Sei Investments Co., Vanguard Group Inc., Envestnet Asset Management Inc., Ownership Capital B.V., and Swiss National Bank.
View insider buying and selling activity for Abiomed or or view top insider-buying stocks.

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABMD stock can currently be purchased for approximately $255.40.

Abiomed (NASDAQ:ABMD) has a market capitalization of $11.64 billion and generates $1.03 billion in revenue each year. The medical equipment provider earns $136.51 million in net income (profit) each year or $2.96 on an earnings per share basis.

Abiomed employs 2,003 workers across the globe.

Abiomed was founded in 1981.

Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The official website for Abiomed is www.abiomed.com. The medical equipment provider can be reached via phone at (978) 646-1400, via email at [email protected], or via fax at 978-777-8411.